BIOGEN INC.
Wolfe Research upgraded Biogen (BIIB) to Outperform from Peer Perform and set a $300 price target, citing strength in the company’s pipeline. The article also notes Biogen completed the RayThera deal, valued at up to $1 billion, adding immunology assets and an anti-inflammatory program entering Phase 1. It cites BIIB Q2 2026 revenue of $2.7B (+3.42% YoY).
Wolfe Research upgraded Biogen and AbbVie to Outperform, setting $300 price targets for each. For Biogen, it cited late-stage pipeline catalysts for litifilimab and felzartamab and said the Apellis acquisition strengthens near-term revenue. For AbbVie, it cited valuation, limited near-term loss-of-exclusivity risk, and multiple upcoming clinical catalysts.
At the AWIR annual conference, Richard A. Furie of Northwell Health said novel therapies are needed to reduce lupus morbidity and mortality, with unmet needs including lupus nephritis. He cited anifrolumab (AstraZeneca) subcutaneous results (56% BICLA vs 37% placebo) and discussed trials for litifilimab, enpatoran, belimumab, obinutuzumab, and CAR T-cells.
Over the past 7 days, alphai's AI scored 9 news stories mentioning BIIB (BIOGEN INC.). Coverage has skewed bullish: 5 bullish, 2 neutral, and 2 bearish.
Recent BIIB coverage spans sector analysis, financial news and regulation.
In the last 30 days, BIIB insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($240K). The most active reporter was Minor Lloyd with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Near-term sentiment tailwind from the upgrade and target, with additional support from the completed RayThera deal adding Phase 1 immunology assets.
Upgrade and catalyst framing can support near-term momentum, but magnitude depends on how investors price upcoming readouts.
Reinforces a catalyst timeline for Biogen’s lupus program, but provides no new phase 3 results yet.
Irish state funding denial risk for Skyclarys could pressure near-term demand assumptions and pricing leverage for Biogen in Europe.
Ireland’s HSE Drugs Group is not recommending reimbursement for Biogen’s Skyclarys at the current price, implying pricing pressure and potential revenue timing risk in that market.
alphai scores every news story that mentions BIIB with an AI model for sentiment and relevance, and aggregates insider trades from BIOGEN INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wolfe Research upgraded Biogen (BIIB) to Outperform from Peer Perform and set a $300 price target, citing strength in the company’s pipeline. The article also notes Biogen completed the RayThera deal, valued at up to $1 billion, adding immunology assets and an anti-inflammatory program entering Phase 1. It cites BIIB Q2 2026 revenue of $2.7B (+3.42% YoY).
3 min readWolfe Research upgraded Biogen and AbbVie to Outperform, setting $300 price targets for each. For Biogen, it cited late-stage pipeline catalysts for litifilimab and felzartamab and said the Apellis acquisition strengthens near-term revenue. For AbbVie, it cited valuation, limited near-term loss-of-exclusivity risk, and multiple upcoming clinical catalysts.
3 min readAt the AWIR annual conference, Richard A. Furie of Northwell Health said novel therapies are needed to reduce lupus morbidity and mortality, with unmet needs including lupus nephritis. He cited anifrolumab (AstraZeneca) subcutaneous results (56% BICLA vs 37% placebo) and discussed trials for litifilimab, enpatoran, belimumab, obinutuzumab, and CAR T-cells.
6 min readIreland’s HSE Drugs Group recommended that the State not fund Skyclarys, a treatment for Friedreich’s ataxia. According to the HSE, the proposed price is substantially above what is considered cost-effective in Ireland, though the therapy is available in several other European countries. The manufacturer Biogen is cited as needing further work in talks with the HSE.
3 min readIreland’s HSE Drugs Group decided not to recommend reimbursement of Biogen’s Skyclarys (for Friedreich’s Ataxia), citing cost effectiveness. NCPE said HSE would need a significant price reduction versus projected €160m budget impact. Costs cited include ~€280,000 per patient per year and ~€130m over five years. Final HSE leadership decision is set for 25 August.
4 min readBiogen (NASDAQ:BIIB) reported Q2 2026 revenue of $2.7B, up 3% year over year. GAAP EPS was $0.66, down from $4.33; non-GAAP EPS was $3.60, down 34%. Growth portfolio revenue rose to $1.1B. Full-year revenue guidance was revised to a mid-single-digit increase, and non-GAAP EPS guidance is $12.00 to $13.00. Net debt was $6.8B after the Apellis deal.
7 min readaTyr Pharma said it will restructure and cut workforce to fund its planned Phase III efzofitimod program. General counsel Nancy Denyes will step down Sept. 30, 2026, and consult. Biogen named Michael Parini chief legal officer. City Therapeutics appointed Mary Beth DeLena. CytomX named Alejandra Carvajal. Sanofi named Jamie Haney executive VP and general counsel.
4 min readGlobal drugmakers plan major U.S. manufacturing and R&D expansions, citing supply-chain resilience and tariff risk. The article says companies including Pfizer, GSK, Eli Lilly, J&J, Roche, AstraZeneca, Novartis, Sanofi, Biogen, Merck, Amgen, AbbVie, Gilead, Bristol Myers Squibb, Cipla, and CSL have pledged about US$500 billion. Examples include Pfizer’s US$70B, Lilly’s US$27B-plus, and Merck’s US$70B-plus.
7 min readBiogen and Ionis’ tofersen (Qalsody) for SOD1-ALS is linked to stabilization or improvement in some patients, including a reported case of reversal after dose escalation. Qalsody was FDA approved in April 2023 based on biomarker data and is marketed in the US and Canada. AL-S Pharma’s AP-101 is also in trials.
7 min readBiogen Inc. (Nasdaq: BIIB) said it has completed its acquisition of RayThera Inc., a privately held immunology-focused biotech. Biogen said the deal adds multiple small-molecule assets to its immunology pipeline, with a lead program that entered Phase 1 development in July 2026. The company did not provide deal terms.
2 min read
